SP 8.17 Safety of Continuing Biological Therapies in IBD Patients Undergoing Elective Surgery: The UK Multicentre SABRE-IBD Study
Rattachement africain : gb. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Abstract Background Evidence guiding peri-operative continuation or cessation of biologics in inflammatory bowel disease (IBD) is limited. Continuation may increase post-operative complications, whereas interruption may precipitate disease flares. Methods We conducted a trainee-led and -delivered, national, multicentre observational study of IBD patients undergoing moderate-to-high risk elective surgery. Patients were stratified into: no biologic therapy (A), biologics paused pre-operatively (≥1 missed dose) (B), or biologics continued (C). Demographics, medications, operative details, complications and flares were recorded anonymously for consecutive cases in 45 NHS trusts. Primary outcome was 90-day post-operative complication rate; secondary outcome was 90-day clinically-relevant IBD flares. Results Data were available for 1,416 patients who underwent surgery August 2016–September 2025. Most procedures were colorectal (70.9%; 88.3% IBD-related), gynaecological (10.2%) and orthopaedic (8.6%). Overall, 53.1% were not on biologics (A), 17.9% paused (B), and 29.0% continued (C). Baseline risk factors, including ASA grade, BMI and pre-operative prednisolone use, were comparable. Median pre-operative haemoglobin, ferritin and albumin were normal. No significant differences were observed in major complications (A 11.6%, B 13.4%, C 12.8%; p=0.7), non-surgical site infections (3.1%, 5.1%, 2.5%; p=0.2) or surgical site infections (6.2%, 5.1%, 6.4%; p=0.3). Post-operative flares were more frequent in biologic-treated patients overall versus non-biologic patients, but did not differ between paused and continued groups (A 3.2%, B 7.1%, C 7.6%; p=0.02). Conclusions In this large multicentre cohort, continuing biologics pre-operatively did not increase complications or infection risk across gastrointestinal and non-gastrointestinal surgery. Although biologic-treated patients experienced more post-operative flares, temporary cessation did not affect flare risk.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- SP 8.17 Safety of Continuing Biological Therapies in IBD Patients Undergoing Elective Surgery: The UK Multicentre SABRE-IBD Study
- Date Crossref
- 01/08/2026
- Éditeur
- Oxford University Press (OUP)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Maidstone and Tunbridge Wells NHS Trust pays non établi dans la noticeÉtablissement de santé
-
Imperial College London pays non établi dans la noticeUniversité ou école supérieure
-
The London College pays non établi dans la noticeUniversité ou école supérieure
-
University Hospitals Sussex NHS Foundation Trust pays non établi dans la noticeÉtablissement de santé
-
University College London pays non établi dans la noticeUniversité ou école supérieure
-
University of Birmingham pays non établi dans la noticeUniversité ou école supérieure
-
Hull and East Yorkshire Hospitals NHS Trust pays non établi dans la noticeÉtablissement de santé
-
Hull University Teaching Hospitals NHS Trust pays non établi dans la noticeUniversité ou école supérieure
Maidstone and Tunbridge Wells NHS Trust, Imperial College London et The London College, avec 5 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.